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Acinetobacter baumannii is emerging as an important nosocomial pathogen worldwide. We report molecular
epidemiology of 65 carbapenem-nonsusceptible A. baumannii isolates identified from hospitals in New York,
Pennsylvania, Florida, Missouri, Nevada, and California between 2008 and 2009. All isolates were subjected to
pulsed-field gel electrophoresis (PFGE). Select isolates then underwent multilocus sequence typing (MLST).
While the PFGE patterns tended to cluster within each hospital, sequence types (STs) belonging to the clonal
complex 92 (CC92) and the pan-European clonal lineage II (EUII; worldwide clonal lineage 2) were predom-
inant in all hospitals. Of them, ST122 and ST208 were the most common and were found in four of the six
hospitals. Isolates belonging to the pan-European clonal lineages I and III were identified in one hospital each.
Carbapenemase-encoding genes blaOXA-23 and/or ISAba1-blaOXA-51-like were present among the majority of
isolates. These findings suggest that carbapenem-nonsusceptible A. baumannii isolates found in U.S. hospitals
constitute part of the global epidemic driven by CC92, but have unique STs other than ST92, which may be
spreading by means of patient transfer between health care facilities within the United States.
Over the last decade, Acinetobacter baumannii has emerged
to become an important cause of nosocomial infections in
many parts of the world (25). Of great concern is the recent,
remarkable rise in the frequency of carbapenem-nonsuscep-
tible A. baumannii. According to data from the National
Healthcare Safety Network (NHSN) surveillance system, 34%
of A. baumannii isolates surveyed from U.S. hospitals between
2006 and 2008 were resistant to carbapenems, along with at
least three other classes of antimicrobials, including ampicillin-
sulbactam, antipseudomonal penicillins, broad-spectrum ceph-
alosporins, fluoroquinolones, and aminoglycosides (16). In an-
other nationwide survey, nonsusceptibility to carbapenems
increased from 22% in 2002 to 52% in 2008 (20). Carbapenem-
nonsusceptible A. baumannii infections are difficult to manage,
as their therapy relies on salvage agents such as colistin and
tigecycline. However, resistance to these agents is emerging
among carbapenem-nonsusceptible A. baumannii isolates
(8, 24).
Three clonal lineages of A. baumannii, commonly referred
to as the pan-European clonal lineages (EUI, EUII, and
EUIII), have predominated in many European countries since
the 1990s (7). These clonal lineages have subsequently been
identified worldwide, including in the United States (14, 36). It
has thus been proposed to refer to them as the “worldwide”
clonal lineages (WW1, WW2, and WW3) by some investigators
(14).
Various molecular typing methods are employed to study
the molecular epidemiology of A. baumannii. The most com-
monly used technique among them is pulsed-field gel electro-
phoresis (PFGE), which is highly discriminatory. However,
PFGE is not well suited for interlaboratory comparisons unless
the procedures are meticulously standardized (29), and its in-
terpretation may pose a challenge in nonoutbreak situations
(31). Repetitive sequence-based PCR, which is now commer-
cially available, has operating characteristics similar to those of
PFGE for A. baumannii (12, 28). Multilocus sequence typing
(MLST), on the other hand, compares nucleotide sequences of
housekeeping genes among isolates and generates objective
and portable data. Three MLST schemes are currently used.
The first MLST scheme for A. baumannii was published by
Bartual et al. in 2005 (2), and it has subsequently been revised
and employed to study the epidemiology of the organism in
many countries (11, 13, 15, 17, 21, 23, 26, 28, 30). The second
MLST scheme, which shares three of the loci with the original
scheme, was developed by Diancourt et al. at the Pasteur
Institute (http://www.pasteur.fr/recherche/genopole/PF8/mlst
/Abaumannii.html) (6). The third scheme utilizes PCR and
mass spectrometry (9). While MLST is an expensive typing
method due to the need for DNA sequencing, selective use of
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this technique can substantially enhance our understanding of
molecular epidemiology across different hospitals and geo-
graphic areas.
The primary aim of the present study was to investigate the
molecular epidemiology of contemporary carbapenem-nonsus-
ceptible A. baumannii isolates collected from hospitals across
the continental United States using MLST.
MATERIALS AND METHODS
Bacterial isolates. A total of 65 carbapenem-nonsusceptible A. baumannii
isolates were investigated. Only one isolate per patient was included. All isolates
were identified from clinical specimens at hospitals across the United States
between 2008 and 2009. The participating hospitals in New York, Pittsburgh, PA,
and St. Louis, MO, have an ongoing collection of carbapenem-nonsusceptible A.
baumannii isolates. From these hospitals, only one isolate was included for a
given month. The hospitals in Jacksonville, FL, Las Vegas, NV, and Torrance,
Los Angeles County, CA, collected serial carbapenem-nonsusceptible A. bau-
mannii isolates for this study for 1 or 2 months in 2009. Only one isolate was
included from each patient. The isolates were identified as A. baumannii using an
automated instrument in each clinical microbiology laboratory (Microscan Walk-
Away [Siemens Healthcare Diagnostics, Deerfield, IL], Vitek 2 [bioMe´rieux,
Durham, NC], or Phoenix 100 [BD, Franklin Lakes, NJ]). The identification as
A. baumannii was subsequently confirmed by detection of blaOXA-51-like by PCR
in the research laboratory (34). In addition, nonsusceptibility to carbapenems
was confirmed by resistance to imipenem and/or meropenem using the disk
diffusion method in the research laboratory located at the University of Pitts-
burgh.
Susceptibility testing. Susceptibility testing was performed following the meth-
odology and breakpoints defined by the Clinical and Laboratory Standards In-
stitute (CLSI) (5). Disk diffusion testing was used for the following agents:
ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, cefepime, imipenem,
meropenem, ciprofloxacin, gentamicin, and amikacin. For tigecycline, the Food
and Drug Administration (FDA) breakpoints for Enterobacteriaceae (14 mm,
resistant; 19 mm, susceptible) were used. In addition, MICs were determined
for imipenem and meropenem using the agar dilution method.
PFGE and MLST. Pulsed-field gel electrophoresis (PFGE) was conducted
using a CHEF DR III system (Bio-Rad, Hercules, CA) using ApaI as the
restriction enzyme, as described previously (1). Bionumerics version 6.01 (Ap-
plied Maths, Sint-Martens-Latem, Belgium) was used for pattern analysis, which
utilizes the unweighted-pair group method. There are currently two multilocus
sequence typing (MLST) schemes for A. baumannii which are widely utilized:
one described by Bartual et al. (http://pubmlst.org/abaumannii/) (2) and one
developed at the Pasteur Institute (http://www.pasteur.fr/mlst) (6). The two
schemes share three of the seven loci. For the present study, we primarily used
the Bartual scheme with modification of the primer sequences proposed by
Martinovich et al. (19). For the purpose of comparison, we then selected one
isolate from each sequence type (ST) obtained by the Bartual scheme and
determined the corresponding ST based on the Pasteur Institute scheme. The
new alleles and STs identified through this study have been deposited into the
relevant databases. The relationship among the new and existing STs was sur-
veyed by the use of the eBURST program (http://eburst.mlst.net/) (10).
PCR and sequencing of carbapenemase-encoding genes. Detection of
blaOXA-51-like and the ISAba1/blaOXA-51-like complex was performed by PCR
using primer sets and conditions described previously (18, 33). The presence of
the ISAba1/blaOXA-51-like complex has been implicated in various degrees of
carbapenem resistance in A. baumannii (33). PCR for the blaOXA-23, blaOXA-40,
and blaOXA-58 genes, the three major groups of acquired carbapenamase-encod-
ing genes that confer clinically relevant resistance to carbapenems, was con-
ducted using a multiplex scheme (38). For sequencing, the full structural genes
of blaOXA-23 and blaOXA-40 were amplified using primers described previously
(18). Sequencing was performed on a 3730 DNA analyzer (Life Technologies,
Carlsbad, CA).
RESULTS
Susceptibility of the carbapenem-nonsusceptible A. bauman-
nii isolates. Of a total of 67 isolates in the initial collection, two
were found to be susceptible to both imipenem and mero-
penem in the research laboratory and were excluded. All of the
remaining 65 isolates were positive for blaOXA-51-like by PCR.
The numbers of isolates from each participating hospital were
as follows: New York, 12; Pittsburgh, 10; St. Louis, 13; Jack-
sonville, 6; Las Vegas, 14; and Los Angeles, 10. The isolates
were identified from various sources, including blood, sputum,
bronchoalveolar lavage, wound, and urine specimens.
Susceptibility testing results of the study isolates are shown
in Table 1. All isolates were nonsusceptible to meropenem,
whereas 16 isolates (25%) were susceptible to imipenem by the
disk diffusion method. All 5 isolates that were intermediate to
meropenem were susceptible to imipenem. Most isolates were
nonsusceptible to -lactams other than carbapenems, includ-
ing piperacillin-tazobactam, ceftazidime, and cefepime. Of the
-lactams, susceptibility to ampicillin-sulbactam was relatively
conserved, with 51% of the isolates being susceptible and an-
other 26% intermediate. All isolates were susceptible to tige-
cycline when using the breakpoint for Enterobacteriaceae de-
fined by the FDA. The MIC50 and MIC90 of imipenem were 16
and 64 g/ml, respectively, whereas MIC50 and MIC90 of
meropenem were 32 and 128 g/ml, respectively (Table 2).
Molecular typing. The results of PFGE and MLST are sum-
marized in Fig. 1, along with the information on the specimen
sources and the hospital locations.
PFGE. PFGE was performed on all 65 isolates. Using a cutoff
of 80% similarity, the isolates were grouped into 24 clusters (Fig.
1). The largest cluster contained 13 isolates from St. Louis and
Pittsburgh. The second and third largest clusters had 7 and 6
isolates from New York and Los Angeles, respectively. Only one
other cluster contained isolates from more than one hospital (one
isolate each from Pittsburgh and Las Vegas).
MLST. (i) Bartual scheme. At least one isolate from each
cluster was selected for MLST. Overall, 36 of the 65 isolates
were typed by MLST under the Bartual scheme. The STs
TABLE 1. Susceptibility of 65 carbapenem-nonsusceptible A.
baumanni isolates determined by the disk diffusion method
Antimicrobial
Susceptibility; no. (%) of isolates:
Susceptible Intermediate Resistant
Ampicillin-sulbactam 33 (50.8) 17 (26.2) 15 (23.0)
Piperacillin-tazobactam 1 (1.5) 0 (0) 64 (98.5)
Ceftazidime 3 (4.6) 3 (4.6) 59 (90.8)
Cefepime 2 (3.1) 17 (26.1) 46 (70.8)
Imipenem 16 (24.6) 8 (12.3) 41 (63.1)
Meropenem 0 (0) 5 (7.7) 60 (92.3)
Ciprofloxacin 0 (0) 0 (0) 65 (100)
Gentamicin 13 (20.0) 0 (0) 52 (80.0)
Amikacin 16 (24.6) 5 (7.7) 44 (67.7)
Tigecycline 65 (100) 0 (0) 0 (0)
TABLE 2. MICs of imipenem and meropenem for the 65 study
isolates determined by the agar dilution method
Antimicrobial
No. of isolates with MIC (g/ml) of: MIC(g/ml)a
1 2 4 8 16 32 64 128 128 50% 90%
Imipenem 1 3 14 7 23 10 6 1 0 16 64
Meropenem 0 1 1 10 7 28 8 7 3 32 128
a 50% and 90%, MIC50 and MIC90, respectively.
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FIG. 1. PFGE and MLST results from the carbapenem-nonsusceptible study isolates. STs are based on the Bartual scheme.
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identified included ST122 to -124, which we recently reported
in isolates from Pittsburgh (32), as well as ST203 to -208 and
ST345, which are new STs that were identified in the present
study. The alleles and STs described in this study are summa-
rized in Table 3.
ST122 was the most commonly observed ST, accounting for
14 of 36 isolates that were typed by MLST, followed by ST208,
which was identified in 9 isolates. Both ST122 and -208 were
found in four of the six hospitals. These STs belong to EUII
and clonal complex 92 (CC92). CC92 is the most prevalent
clonal complex worldwide, encompassing over 50 STs that have
been identified from many countries, including some from the
United States (11, 13, 15, 17, 21, 23, 28, 32, 37). The next most
common ST was ST204 (4 isolates), which along with ST206 (1
isolate) comprised isolates from three hospitals and also be-
longed to CC92. Three isolates belonged to CC113, which is
commonly reported from Argentina and Brazil (http://pubmlst
.org/abaumannii/) (12a). They included ST124 (1 isolate) and
ST205 (2 isolates) from two hospitals. There were three sin-
gleton STs, ST203, ST207, and ST345. ST203 was identified
from New York and belonged to EUIII. ST207 was identified
from Los Angeles as a DLV of STs within CC109, which belongs
to EUI. CC109 has been identified worldwide, including Europe,
East Asia, and South America (http://pubmlst.org/abaumannii/).
ST345, which was found in an isolate from Las Vegas, could not
be categorized according to any of the three major pan-European
clonal lineages based on MLST.
We only determined ST for approximately half of the study
isolates. If we assume that isolates from the same PFGE clus-
ter belong to the same clonal complex, then 55 of the 65
isolates would be assigned to CC92.
(ii) Pasteur Institute scheme. To examine how the two
MLST schemes compare, we then conducted MLST based on
the Pasteur Institute scheme for isolates representing each ST
based on the Bartual scheme. The five STs representing CC92
under the latter scheme were all assigned to ST2 under the
Pasteur Institute scheme (Table 3).
Carbapenemase-encoding genes. Twenty-seven of the 65 iso-
lates (42%) were positive for blaOXA-23 by PCR. Thirteen of
them were subjected to sequencing of the entire gene, and they
were all consistent with OXA-23, underscoring the homogene-
ity of this enzyme. blaOXA-23-positive isolates were found from
all six hospitals and in multiple STs (ST122 and ST204 to -208).
Nine isolates (14%) were positive for blaOXA-40. Seven of them
were from ST123 isolates from New York and were found to
encode OXA-72 upon sequencing, which is a single-amino-acid
variant of OXA-40 (32). The other two isolates were from
Pittsburgh (ST122) and Jacksonville (ST124) and encoded
OXA-40. None of the isolates was positive for blaOXA-58.
Forty-two isolates (65%) were positive for the ISAba1/blaOXA-51-like
complex, which may contribute to carbapenem resistance (33).
Two isolates were negative for any of the carbapenemase genes
mentioned above.
DISCUSSION
It is increasingly recognized that A. baumannii is clonal in
nature and that a large part of the global epidemic of multi-
drug-resistant A. baumannii is driven by strains that belong to
EUII, in particular those defined as CC92 by MLST (11, 15, 17,
21, 23, 28). In the United States, an outbreak of multidrug-
resistant A. baumannii from a hospital in Houston that took
place between 2005 and 2006 was caused by CC92 strains (30).
A survey of bacteremic isolates collected from 52 U.S. hospi-
tals between 1998 and 2004 also showed the preponderance of
CC92 (37). Carbapenem resistance is becoming more and
more common among A. baumannii isolates in U.S. hospitals
in recent years (16, 20). It poses a substantial clinical challenge
as therapeutic options are extremely limited for these organ-
isms. This study was conducted to better understand the molec-













complexgltA gyrB gdhB recA cpn60 gpi rpoD cpn60 fusA gltA pyrG recA rpiB rpoB
122 1 3 61 2 2 7 3 92 2 2 2 2 2 2 2 2 2 Pittsburgh, St. Louis,
Las Vegas,
Jacksonville
123 1 35 61 2 2 3 3 92 2 2 2 2 2 2 2 2 2 New York
124 1 17 60 10 28 66 32 113 79 26 2 2 2 29 4 5 Singleton Jacksonville
203 41 1 72 32 1 98 6 Singleton 124 3 3 2 2 28 1 3 3 New York
204 1 17 61 2 2 99 3 92 2 2 2 2 2 2 2 2 2 New York, Las
Vegas
205 1 17 60 10 28 99 32 113 79 26 2 2 2 29 4 5 Singleton St. Louis,
Jacksonville
206 1 17 72 2 2 99 3 92 2 2 2 2 2 2 2 2 2 Los Angeles
207 10 53 84 11 4 100 5 Singleton 1 1 1 1 1 5 1 1 1 Los Angeles
208 1 3 61 2 2 97 3 92 2 2 2 2 2 2 2 2 2 Pittsburgh, St. Louis,
Los Angeles, Las
Vegas
345 46 12 122 1 16 141 50 Singleton 123 5 2 3 2 3 1 5 Singleton Las Vegas
231 10 12 88 11 4 98 5 Singleton 1 1 1 1 1 5 1 1 1 AYE
207 10 53 84 11 4 100 5 Singleton 1 1 1 1 1 5 1 1 1 AB0057
12 8 4 4 4 4 5 5 Singleton 1 1 1 1 1 5 1 1 1 RUH875
1 12 61 2 2 97 3 92 2 2 2 2 2 2 2 2 2 ACICU
6 1 4 3 2 2 3 3 92 2 2 2 2 2 2 2 2 2 RUH134
112 1 12 56 36 1 61 26 Singleton 77 3 2 2 2 3 4 28 Singleton ATCC 17978
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ular epidemiology of carbapenem-nonsusceptibleA. baumannii in
U.S. hospitals, with the aim of identifying predominant clonal
lineages currently circulating in this country.
Our analysis revealed CC92 to be the most prevalent clonal
complex, identified in isolates from all 6 participating hospitals.
Interestingly, however, ST92, the predicted founder of CC92
and reported from a number of European and East Asian
countries as well as Australia, was not found in this study.
Instead, ST122, ST123, ST204, ST206, and ST208 were iden-
tified as CC92 STs, with predominance of ST122 and ST208,
both of which were found in 4 of the 6 participating hospitals.
While ST123 was only found in the hospital in New York in
this study, we previously reported this ST from an isolate in
Pittsburgh (32). To our knowledge, these STs have not been
identified outside the United States. Furthermore, they share a
novel gdhB allele encoding quinoprotein glucose dehydroge-
nase B (allele 61), with the exception of ST206. Taken to-
gether, these findings may suggest that the current epidemic of
carbapenem-nonsusceptible CC92 strains in the United States
represents clonal expansion of progenitor strains, which was
likely facilitated by patient transfer, rather than repeated im-
portation of CC92 strains from overseas. The other clonal
complex identified in this study was CC113 (ST124 and
ST205). Only two singletons were identified from the other
pan-European lineages: ST203 from New York (EUIII) and
ST207 from Los Angeles (EUI), further underscoring the
clonal nature of carbapenem-nonsusceptible A. baumannii iso-
lates currently circulating in the United States.
While MLST is a powerful molecular typing methodology,
its cost could be forbidding for routine use. We opted to first
group isolates by PFGE, which is more discriminatory than
MLST, and then subject representative isolates from each
pulse type to MLST. As can be seen in Fig. 1, the isolates from
the same hospital tended to cluster together. There were also
some instances where isolates from different hospitals could be
categorized as the same pulse type (e.g., ST122 isolates from
Pittsburgh and St. Louis), but the PFGE patterns were gener-
ally diverse for isolates from different hospitals, even when the
STs were identical. This finding is in line with the operating
characteristics of these two typing methods, where PFGE is
well suited for studying isolates from a defined temporal and
spatial epidemiologic setting, whereas MLST has an advantage
in defining clonal lineages of isolates from larger geographic
areas over time.
It has been suggested that two MLST loci used in the Bar-
tual scheme (gyrB and gpi) are prone to recombination (13). In
our comparison of the two MLST schemes, ST2 under the
Pasteur Institute scheme was represented by 5 STs under the
Bartual scheme. This variation resulted from the presence of 4,
3, and 2 alleles at the gpi, gyrB, and gdhB loci in the Bartual
scheme, respectively. We did not have enough STs in EUI and
EUIII to make a useful comparison.
As expected, blaOXA-23 was the most common carbapen-
emase-encoding gene, which was found across different clonal
complexes of carbapenem-nonsusceptible isolates from all hos-
pitals. Globally, blaOXA-23 is the most prevalent acquired car-
bapenemase-encoding gene that is associated with carbapenem
resistance (21). blaOXA-40 and its variant blaOXA-72 were found
in isolates from three hospitals. The finding of isolates with
blaOXA-23 and blaOXA-72 from the hospital in New York was
noteworthy, since a previous comprehensive study describing
resistance mechanisms of 40 multidrug-resistant A. baumannii
isolates collected from hospitals in the area between 2001 and
2006 did not reveal the presence of acquired OXA-type car-
bapenemase-encoding genes (4). It is thus possible that an
ST204 strain with blaOXA-23 and an ST123 strain with
blaOXA-72 were introduced in the area between the two study
periods.
While the primary scope of this study was molecular epide-
miology, we also found that susceptibility to ampicillin-sulbac-
tam was maintained in 33 of 65 isolates, all of which were
nonsusceptible to at least one carbapenem tested. They in-
cluded 12 blaOXA-23-positive isolates, 2 blaOXA-40-positive iso-
lates, and 7 blaOXA-72-positive isolates. Sulbactam, the -lac-
tamase inhibitor component of this formulation, is known to
have intrinsic activity against A. baumannii, which is believed
to be due to its high affinity to certain penicillin-binding pro-
teins (35). Several clinical studies have suggested that ampicil-
lin-sulbactam may be clinically efficacious in the management
of infections due to carbapenem-resistant A. baumannii (3, 22).
While susceptibility to tigecycline was maintained well, we
included only the initial isolate from each patient for this study.
Since resistance to tigecycline may develop in subsequent iso-
lates after exposure to this agent (24, 27), our results may
underestimate the prevalence of nonsusceptibility on a per
case basis.
The limitation of our study was that the isolates were col-
lected in a relatively brief time period at some of the partici-
pating hospitals, which may not represent the overall epidemi-
ology of carbapenem-nonsusceptible A. baumannii at those
hospitals. Based on our findings, we plan to conduct a longi-
tudinal surveillance study to further elucidate the epidemiol-
ogy of this organism in the United States.
In conclusion, STs representing CC92 appear to be predom-
inant among carbapenem-nonsusceptible A. baumannii iso-
lates in U.S. hospitals, suggesting that they constitute part of
the global epidemic driven by this clonal complex belonging to
EUII. However, the finding that STs in CC92 were not ST92
but predominantly ST122 and ST208, which are thus far
unique to the United States, suggests that these organisms may
be spreading through transfer of colonized patients between
health care facilities within the country.
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